丹麦、挪威、瑞典和威尔士胶质瘤患者的精神药物使用情况
该研究基于丹麦(2001-2016)、挪威(2006-2019)、瑞典(2008-2018)和威尔士(2005-2016)的数据,纳入16,007例胶质瘤患者,并按年龄和性别匹配无癌对照队列,评估胶质瘤诊断前后2年内精神药物新处方率。结果显示,新使用精神药物的比例自诊断前7个月开始上升,在诊断当月达峰(峰值范围为每1000人月227至753种新精神药物),诊断后2年内虽持续下降但仍显著高于对照,且主要由抗癫痫药、抗焦虑药、催眠药和镇静药驱动。
要点
- 胶质瘤患者诊断前7个月精神药物新使用率开始上升,诊断当月达峰。
- 诊断后2年内新使用率持续下降,但仍显著高于年龄性别匹配的无癌对照。
- 新使用主要由抗癫痫药、抗焦虑药、催眠药和镇静药驱动。
核心结论
- 胶质瘤患者精神药物使用率高,诊断前后出现的升高主要由抗癫痫药、抗焦虑药、催眠药和镇静药驱动,可能与疾病后果相关。
研究设计与样本
- 基于丹麦(2001-2016)、挪威(2006-2019)、瑞典(2008-2018)和威尔士(2005-2016)人群登记数据,识别16,007例胶质瘤患者,并按年龄和性别匹配无癌对照队列。
主要发现
- 新使用精神药物的比例自诊断前7个月开始上升,诊断当月达峰,峰值范围为每1000人月227至753种新精神药物。
- 诊断后2年随访期内,胶质瘤患者新使用率仍显著高于对照,但持续下降。
- 新使用主要由抗癫痫药、抗焦虑药、催眠药和镇静药驱动。
- 按组织学亚型分层分析,模式相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioma patients often suffer from psychiatric and neurological conditions. However, little is known about the patterns of use of psychotropic drugs pre- and post-glioma diagnosis. Therefore, we assessed temporal patterns of psychotropic prescriptions among glioma patients, compared to an age and sex matched comparison cohort in four European countries. METHODS: Incident gliomas were identified in Wales from the Secured Anonymized Information Linkage Databank (2005-2016) and population-based registries in Denmark (2001-2016), Norway (2006-2019), and Sweden (2008-2018). From each data source, a cancer-free comparison cohort was matched to the glioma cases by age and sex. We calculated rates of new psychotropic prescriptions and any psychotropic prescriptions during the 2 years prior to and post glioma diagnosis. Analyses were stratified by histological subtypes and subclasses of psychotropic medications. RESULTS: We identified 16,007 glioma patients. The rate of new psychotropic drug use increased from 7 months before diagnosis, peaking around the month of glioma diagnosis (with peak rates ranging from 227 to 753 new psychotropic drugs per 1000 person-months). New use remained substantially higher among glioma patients than comparators throughout the 2-year follow-up period after glioma diagnosis, though rates of new use continued to decline throughout. New use was largely driven by antiepileptics, anxiolytics, hypnotics, and sedatives. Patterns were similar when analyses were stratified by histological subtype. CONCLUSION: Psychotropic drug use among glioma patients was high, and elevations observed around the time of cancer diagnosis, largely driven by antiepileptics, anxiolytics, hypnotics, and sedatives, are likely associated with the consequences of the disease.
引用
- Baxter SM, Bjørge T, Bjerkvig R, et al. Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales. J Neurooncol. 2025. PMID: 40208515. doi:10.1007/s11060-025-04996-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。